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The current vaccination strategy against influenza A
and B viruses is vulnerable to the unanticipated emergence
of epidemic strains that are poorly matched by the vaccine.
A vaccine that is less sensitive to the antigenic evolution of
the virus would be a major improvement. The general fea-
sibility of this goal is supported by studies in animal models
that show that immunologic activities directed against rela-
tively invariant viral determinants can reduce illness and
death. The most promising approaches are based on anti-
bodies specific for the relatively conserved ectodomain of
matrix protein 2 and the intersubunit region of hemagglu-
tinin. However, additional conserved determinants for pro-
tective antibodies are likely to exist, and their identification
should be encouraged. Most importantly, infection and cur-
rent vaccines do not appear to effectively induce these anti-
bodies in humans. This finding provides a powerful
rationale for testing the protective activity of these relative-
ly conserved viral components in humans. 
C
urrent influenza virus vaccines attempt to induce
strong antibody responses against the viral glycopro-
teins hemagglutinin (HA) and, with lesser emphasis, neu-
raminidase (NA) because their protective efficacy is well
documented. Thus, typical HA-specific antibodies neutral-
ize viral infectivity and fully protect against infection
when they are present at sufficient concentration in the lin-
ing fluid of the respiratory tract, and typical NA-specific
antibodies inhibit the release of newly formed virus from
infected host cells and thus limit the spread and shedding
of virus during infection. Current vaccines are highly
effective in children and adults (70%–90%), although not
in those >65 years of age (30%–50%) (1). Apart from their
limited efficacy in the elderly, a major drawback of current
vaccines is that the principal vaccine targets, most notably
the distal region of HA, are subject to continuous alteration
in circulating epidemic virus strains (2,3). This process,
termed antigenic drift, results from the high mutation rate
of the viral genome and the continuous selection of
mutants with improved replication characteristics in the
immune human host population. On average, the prevalent
influenza A virus strain acquires 3–4 amino acid changes
per year in HA, with most being located in the regions rec-
ognized by protective antibodies. Every 2 to 5 years, the
accumulation of mutations results in a major antigenic drift
away from the previously circulating strains (4). A more
drastic antigenic change, termed antigenic shift, occurs if a
new HAsubtype is introduced into the pool of human virus
strains by reassortment of genes between animal and
human strains or by direct transmission of strains from an
animal reservoir to humans, as has occurred recently with
strains of H5N1, H7N7, and H9N2 (1). Accordingly, the
influenza vaccine must be updated on a regular basis to
reflect the antigenic changes that occur in the pool of cir-
culating virus strains. Because vaccines have to be manu-
factured before the actual epidemic strains are known, a
failure to anticipate emergence of a strain with major anti-
genic drift or shift relative to the vaccine will result in a
substantial reduction or abrogation of vaccine-mediated
protection. 
While antibodies to the immunodominant, but highly
variable, regions of HA and NA can provide potent virus
strain–specific protection, the existence of weaker and
more broadly protective immune activities directed to less
variable regions of viral proteins has long been known (5).
These protective activities have collectively been termed
heterotypic or heterosubtypic immunity because they pro-
vide a measure of protection against viruses of distinct
subtypes. Because of their potential for broadening vac-
cine-mediated protection in humans, they have been stud-
ied extensively in animals and found to be mediated
predominantly by virus-specific memory T cells (6,7),
antibodies (8–10), or a combination of both (11–13). The
reason for these differences in the relative strength of T-
cell and antibody-mediated protection is not clear but
could be attributable to differences in vaccination
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was measured) between the various studies. Pros and cons
of some of these activities in terms of their potential for
development of a broadly protective, “universal” influenza
vaccine are briefly discussed below. 
Memory T Cells 
A large fraction of the virus-specific T-cell response in
mice and humans is directed to conserved determinants of
viral core proteins, and many studies in mice have shown
that memory T cells can accelerate recovery and reduce ill-
ness on virus challenge. Cytotoxic T (Tc) cells were found
to be more protective than helper T cells, and among Tc
cells, protective activity was shown to depend on their fre-
quency (number of virus-specific cells/total cells),
cytokine secretion profile, memory type (central vs. effec-
tor), and even fine specificity. However, in contrast to find-
ings in mice, the protective value of memory Tc cells in
humans remains controversial. The classic study by
McMichael et al. (14) indicated that presence of memory
Tc cells in blood, which could give rise to Tc cells on stim-
ulation in vitro, correlated with reduced virus shedding
3–4 days after volunteers were challenged with a wild-type
virus, but had no significant effect on illness. Subsequent
studies performed in children found no significant differ-
ence in shedding of attenuated vaccine strains in patients
who had recovered from previous infection with a vaccine
or natural strain of a different subtype than did study par-
ticipants who had no evidence of previous virus exposure
(15,16). Similarly, children vaccinated with an H1N1
strain showed no difference in attack rate and febrile respi-
ratory illness during exposure to natural epidemic H3N2
virus from controls who received a placebo (17). 
Although the presence of memory Tc cells in the vacci-
nated children was not demonstrated experimentally, it can
be implied based on findings that infection with a live,
attenuated vaccine or natural virus strain typically stimu-
lates a Tc-cell response in humans. Taken together with the
observation that the degree of antigenic change (drift,
shift) is a major determinant of epidemic severity, little
evidence exists for a substantial protective role of subtype
cross-reactive memory Tc cells in human influenza virus
infection; the contribution of Tc cells per se in the control
of the infection is not questioned, only whether memory Tc
cells provide a further improvement. 
Vaccine-induced or natural upper respiratory tract
infection in humans may not engender an optimally protec-
tive memory Tc-cell population because of insufficient
number or composition. However, a large number of mem-
ory T cells may also result in immunopathologic manifes-
tations (14,18), which tend to be associated with excessive
inflammatory responses in acute infections. Thus, a uni-
versal vaccine based on the induction of a strong memory-
Tc response might necessitate a difficult balancing act
between protection and immunopathologic changes.
Unless one can identify a particularly protective memory
Tc-cell population that is poorly induced by natural or vac-
cine-induced infection, the nondiscriminatory enhance-
ment of memory T-cell populations may not be a
promising approach for a universal influenza vaccine. 
Antibodies Specific for Conserved 
Viral Determinants
A precondition for antibody-mediated protection is the
accessibility of the viral antigen to antibody on infectious
virus particles, intact infected cells, or both. This accessi-
bility restricts the potential targets to conserved structures
of the ectodomains of viral transmembrane proteins HA,
NA, and M2, in the case of influenza A viruses, and HA,
NA, NB, and BM2, in the case of influenza B viruses.
Results of studies reported thus far have focused on M2 of
influenza A and HA of influenza A and B viruses. 
M2 of Influenza A Viruses 
M2 forms tetramers that exhibit pH-inducible proton
transport activity. It regulates the pH of the viral core after
virus uptake into the host cell’s endosomal compartment
during initiation of infection and subsequently of vesicles
that transport the viral transmembrane proteins to the cell
surface during the late stage of infection. M2 tetramers are
expressed at high density in the plasma membrane of
infected cells and are well accessible to M2e-specific anti-
bodies in this location, but only a few copies become
incorporated into the envelope of mature infectious virus
particles (19,20). M2 has a small, nonglycosylated
ectodomain (M2e) of 23 amino acids (aa), not counting
the posttranslationally removed N-terminal Met. This
region has shown only limited variation among human
influenza A viruses. This remarkable degree of structural
conservation of M2e is attributable mainly to its genetic
relation with matrix protein 1 (M1), the most conserved
protein of influenza A viruses with which it shares coding
sequences. Thus, aa residues 1–9 of M2e and M1 are
encoded by the same nucleotides in the same reading
frame and aa 10–23 of M2e and 239–252 of M1 in a  dif-
ferent reading frame. 
Studies by several groups conducted in mice and ferrets
have shown that M2e-specific antibodies, while they did
not prevent infection, restricted subsequent virus replica-
tion and reduced illness and proportion of deaths (20–24).
This antibody response was only poorly induced by infec-
tion, both in mice (22) and humans (24,25). Alikely reason
for the poor M2e-specific antibody response is extensive
antigenic competition with HA- and NA-specific respons-
es (26). Thus, in view of the >10-fold difference in
ectodomain size, the frequency of M2e-specific precursor
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quencies of HA- and NA-specific precursor B cells.
Assuming that most immunogenic entities generated in the
course of infection contain a mixture of all 3 transmem-
brane proteins, most M2e may be taken up by HA- and
NA-specific B cells, leaving little or none for B-cell recep-
tor–mediated uptake and processing by M2e-specific pre-
cursor B cells. Note that the same phenomenon results also
in a suppression of the NA-specific antibody response by
immunodominant HA-specific B cells (26). Such competi-
tion can be avoided by presenting individual antigens on
physically distinct immunogenic entities to the immune
system (27). The substantial M2e-specific antibody
responses seen in mice after vaccination with dedicated
M2e vaccines (20–24) supports the above explanation.
In view of the poor or absent M2e-specific antibody
response in humans, confirming the genetic stability of
M2e was essential when the virus was propagated in an
immune environment. Replication of A/PR/8/34(H1N1)
(PR8) virus for >3 weeks in severe combined immunode-
ficient (SCID) mice that were chronically treated with
M2e-specific monoclonal antibodies (MAbs) resulted in
the emergence of M2e-escape mutants (28). However,
only 2 distinct escape mutants emerged, 1 with a replace-
ment of Pro at position 10 by Leu (P10L) and the other
with a replacement of the same Pro by His (P10H) (28).
Each of these mutants was isolated repetitively from many
distinct mice treated with distinct M2e-specific MAbs,
which indicates that they represented essentially the entire
range of escape mutants capable of arising from the PR8
wild-type virus under the given experimental conditions.
No escape mutants emerged after 11 consecutive passages
of PR8 in BALB/c mice that had been actively vaccinated
with M2e (unpub. data). In addition, incorporating deter-
minants of potential escape mutants into a polyvalent uni-
versal M2e vaccine would likely further impede
emergence of escape mutants. Indeed, preliminary studies
have shown that no escape mutants emerged in SCID mice
treated with a combination of MAbs specific for M2e of
wild-type PR8 and the P10H and P10L escape mutants
(unpub. data). Thus, although M2e is not totally invariant,
it is remarkably stable, even under immune pressure.
Several vaccination strategies have been evaluated in
mouse and ferret models, including M2-expressing recom-
binant viruses, M2 recombinant proteins (20,21), M2-
encoding plasmid DNA (29), and synthetic M2e peptides
that were chemically linked to carrier proteins or syntheti-
cally linked to defined helper T-cell determinants (22–24).
In most studies in which induction of an antibody response
was confirmed, M2e-specific immunity reduced illness,
but did not entirely prevent it. The best protection was
reported for mice vaccinated by the intranasal route with
an M2e-hepatitis B core fusion protein construct and
detoxified heat-labile Escherichia coli enterotoxin adju-
vant; almost none of these mice died after a virus challenge
that killed 90% of control mice (21). However, in contrast
to the significant protection seen in most mouse models,
pigs vaccinated with recombinant M2e-hepatitis B core
protein or plasmid DNA encoding an M2e-nucleoprotein
fusion protein showed no protection or even had higher
death rates, respectively, after virus challenge (29). This
finding needs to be confirmed, and the explanation for it
remains unknown. At this time, it serves as a reminder that
immune phenomena are complex and that observations
made in 1 species may not apply to another. By the same
token, good protection in an animal model does not guar-
antee protection in humans.
Taken together, the observations that M2e shows mini-
mal antigenic variability, even under antibody-mediated
pressure in vivo, that M2e-specific antibodies typically
restrict virus replication in vivo, and that humans exhibit
low or undetectable M2e-specific antibody titers provide a
strong rationale for further exploration of an M2e-based
vaccine. 
HA of Influenza A and B Viruses 
The HAmolecule has a large ectodomain of ≈500 aa. A
posttranslational cleavage by host-derived enzymes gener-
ates 2 polypeptides that remain linked by a disulfide bond.
The larger N-terminal fragment (HA1, 320–330 aa) forms
a membrane-distal globular domain that contains the
receptor-binding site and most determinants recognized by
virus-neutralizing antibodies. The smaller C-terminal por-
tion (HA2, ≈180 aa, excluding transmembrane and cyto-
plasmic domain) forms a stemlike structure that anchors
the globular domain to the cellular or viral membrane.
Sixteen HA subtypes have been identified among influen-
za A viruses (30); 3 of these (H1, H2, H3) have been asso-
ciated with classic influenza isolates, and 3 (H5, H7, H9)
have been associated with recent sporadic human isolates
(1). Influenza B viruses possess only 1 HA subtype.
Although the degree of sequence diversity between
subtypes is great, particularly in the HA1 polypeptides
(34%–59% homology between subtypes), more conserved
regions are found in HA2 (51%–80% homology between
subtypes). The most notable region of conservation is the
sequence around the cleavage site, particularly the HA2 N-
terminal 11 aa, termed fusion peptide, which is conserved
among all influenza A subtypes and differs only by 2 con-
servative aa replacements in influenza B virus. Part of this
region is exposed as a surface loop in the HA precursor
molecule (HA0) (31). However, when HA0 is cleaved into
HA1/HA2, the newly generated terminals separate, and the
hydrophobic fusion peptide becomes tucked into a cavity
of the stem (31). As most HA subtypes are cleaved by
extracellular enzymes, this surface loop may be accessible
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plasma membrane of infected host cells. The protective
potential of antibodies directed to this region of HA0 has
been explored in 2 studies by immunization of mice with
synthetic peptides spanning the cleavage site (32,33). Both
studies found that mice vaccinated with a peptide spanning
the HA1/HA2 joining region exhibited less illness and
fewer deaths on virus challenge (32,33). Most importantly,
HA1/HA2 joint-specific antibodies were undetectable in
virus-immune human sera (33). These findings make the
HA1/HA2 joining region another promising candidate for
inclusion in a universal vaccine. Indeed, the authors of 1
study, some of whom had been involved in an M2e-vac-
cine study, commented that joint-specific immunity in the
mouse model was more robust than M2e-specific immuni-
ty (33). 
Although the HA1/HA2-joining region is the most
broadly conserved HA sequence, other determinants on
HA2 are shared between a restricted number of subtypes.
For instance, a MAb that reduced illness and death in pas-
sively immunized mice against viruses of the H1, H2, and
H5 subtypes has been described (34,35). This MAb was
shown to recognize a conformational epitope of HA2 (36),
but no immunogen that could selectively induce this
response has been described. A search for determinants
shared by a more restricted number of closely related sub-
types such as H2 and H5, which display 85% sequence
homology in HA2, or shared by members of the same sub-
type, which typically display >95% sequence homology in
HA2 (30), would be worthwhile, particularly since the
HA2-specific antibody response appears to be induced less
effectively than the HA1-specific response by infection in
humans (37). That many HA2-specific antibodies do not
display substantial antiviral activities in vitro does not pre-
clude protective activity in vivo because the mere binding
of antibody to native HA expressed on infected cells and
infectious virus could mediate protective activity by target-
ing Fc-receptor expressing cells or complement deposition
to these structures. 
Other Viral Transmembrane Proteins 
To our knowledge, conserved determinants for protec-
tive antibodies have not been described for any of the other
transmembrane proteins of influenza A and B virus. BM2
of influenza B virus, the homolog of M2, has only a 6-aa-
long ectodomain (38). This ectodomain is most likely too
small for formation of a BM2-specific epitope because
protein epitopes have usually been found to comprise
12–17 contact residues. NB of influenza B virus also
shows structural similarities with M2 of influenza A virus,
including ion channel activity (39), and has an 18-aa-long
ectodomain. However, NB2 has 2 attached carbohydrate
chains that can be expected to mask the protein core from
recognition by antibody. NA, however, is a good and not
sufficiently explored target for cross-protective antibodies.
Like HA, it displays a large ectodomain of ≈420 aa. Nine
subtypes are recognized among influenza A viruses, while
influenza B virus contains 1 subtype. The C-terminal of the
polypeptide (≈380 aa) forms a globular head that is
anchored to the viral membrane by a flexible stalk. The
globular domain contains the enzyme-active site and all
known antigenic sites. 
Although no cross-protective NA-specific antibody
population has been identified, indirect evidence supports
the existence of cross-reactive determinants on N1 and N2,
the subtypes found in classic human strains. Thus, mice
vaccinated first with a mixture of purified N1 and N2 pro-
teins and subsequently boosted with the individual anti-
gens showed a small memory response also against the
heterologous subtype (40). Given the ample expression
and accessibility of NA on infectious virus and infected
host cells, a search for determinants shared between or
within subtypes would be worthwhile.  
Conclusions
Studies in animal models have yielded clear evidence
for the existence of antibody populations that are directed
to relatively invariant determinants of the ectodomains of
viral transmembrane proteins and are capable of substan-
tially reducing, in some cases even preventing, clinical ill-
ness resulting from influenza virus infection. Additional
highly conserved determinants likely exist, particularly on
HA2 and NA polypeptides, which can serve as targets for
protective antibodies. These targets should be identified
for 2 reasons. First, with the exception of the fusion pep-
tide, none of the presently identified “conserved” determi-
nants is totally invariant, and each of these relatively
invariant determinants may show increased variability
under specific immune pressure. Second, incorporation of
several conserved targets in a universal vaccine may
decrease the likelihood and rate of emergence of escape
mutants and increase the strength of protection. 
None of the identified broadly protective antibody pop-
ulations has been found consistently and at appropriate
concentrations in human sera, which indicates that neither
is effectively induced by natural infection or current vac-
cines. Therefore, the observation that heterosubtypic pro-
tection in humans tends to be low does not exclude the
possibility of substantial protection by these antibody pop-
ulations in humans if it can be induced by a specific vac-
cine. A focused search will likely show additional
relatively conserved target structures for protective anti-
bodies. Any of these responses, if not already induced
effectively by infection or current vaccines, will be worth
pursuing for incorporation into a universal vaccine. The
main difficulty may be to develop in each case an immuno-
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body population. However, even if an appropriate vaccine
for induction of a desired broadly protective antibody
response cannot be developed, through this research,
humanized antibody reagents may be generated that can be
used to treat life-threatening human infections. In view of
the potential rewards, the universal vaccine approach
should be further explored in animal models and its protec-
tive efficacy assessed in humans. 
None of the universal vaccines studied thus far in ani-
mal models has achieved the level of protection provided
with current vaccines. Still, an optimized polyvalent uni-
versal vaccine, while not preventing infection, may pre-
vent clinical disease, as has been reported already for 2
vaccination modalities (21,23). If the same results applied
to humans, a universal vaccine might replace the current
vaccine. Alternatively, if a universal vaccine can only
reduce, but not prevent, clinical disease in humans, it could
still be used as adjunct to current vaccines and provide
increased resistance in case of the unanticipated emer-
gence of a major drift variant or new subtype. Newborns,
who are at risk for severe disease, would then receive at
least some protection by maternal antibodies. In the elder-
ly, another high-risk population, a universal vaccine may
be particularly advantageous because the protective anti-
bodies are generated by memory B cells that tend to be
maintained into old age and can be recalled by booster vac-
cination. In contrast, the efficacy of current inactivated
vaccines depends greatly on the ability to mount a strong
response to novel (strain-specific) determinants generated
through antigenic drift and shift on HA and NA. This
response requires naive B cells, whose frequency tends to
decrease with increasing age. When all factors are taken
into account, protection against influenza virus infection
likely can be improved by a universal vaccine.
Dr  Gerhard is a professor in the Immunology Program of
the Wistar Institute. He has worked for the past 30 years on issues
related to the recognition of and protection against influenza
virus by the immune system.
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